医学
原发性硬化性胆管炎
打开标签
肝硬化
原发性胆汁性肝硬化
胃肠病学
内科学
法尼甾体X受体
兴奋剂
受体
临床试验
疾病
化学
生物化学
基因
转录因子
核受体
作者
Cynthia Levy,Stephen H. Caldwell,Parvez Mantry,Velimir A. Luketic,Charles Landis,Jonathan Huang,Edward Mena,Rahul Maheshwari,Kevin Rank,Jun Xu,Vladislav Malkov,Andrew N. Billin,Xiangyu Liu,Xiaomin Lu,William Barchuk,Timothy R. Watkins,Chuhan Chung,Robert P. Myers,Kris V. Kowdley
标识
DOI:10.14309/ctg.0000000000000744
摘要
This proof-of-concept, open-label phase 1b study evaluated the safety and efficacy of cilofexor, a potent selective farnesoid X receptor agonist, in patients with compensated cirrhosis due to primary sclerosing cholangitis.
科研通智能强力驱动
Strongly Powered by AbleSci AI